Importantly, treatment with the pan‐peroxisome proliferator‐activated receptor (PPAR) agonist lanifibranor in the MASLD model significantly lowered the accumulation of CD45R/B220+, IBA1+, IBA1+CLEC4F− and PCNA+ cells, while neither affecting PDGF‐Rβ+ cell accumulation nor IBA1+ cell staining intensities for CCR2 and CD11b (Figure 1B,C; Figure S2D–F, Supporting Information).[19]. This evidence concerns the gene PCNA and metabolic dysfunction-associated steatotic liver disease.